LipidBrick® is a novel range of proprietary cationic lipids dedicated to the formulation of LNPs for the development of mRNA-based vaccines and thera...
Abstract
Lipid nanoparticles (LNP) have demonstrated high efficiency delivering RNA therapeutics in vivo. However, the properties of such nanoparticles obtained with conventional ionizable lipids are often hard to modulate,and especially their biodistribution profile. Such ionizable lipid-based nanoparticles often predominantly end up targeting the liver. One of the current challenges in the field consists of adjusting the particle chemical composition to the targeted application. Here, we have characterized a library of 10 innovative imidazolium-based cationic lipids as key component of cationic LNPs (cLNP). We disclose their chemical structures and demonstrate their efficacy generating LNPs through characterization of their hydrodynamic diameters, Zeta potentials and encapsulation efficiencies. The resulting particles display high transfection efficiencies and have little to no impact on cell viability in vitro, on HEK-293 and CaCo-2 cell lines. In vivo, the biodistribution of the cLNP highly depends on the cationic lipid chemical structures, targeting mainly lungs and spleen. Among this library, we have identified one cationic lipid as a potent additive in Moderna‘s Spikevax formulation.
Other sources
Check our FAQs
These FAQs are organized by application to guide you to find the best answer possible.
Product Documents
You have access to all the documents related to the Polyplus Products such as MSDS, NHPS and Posters.
Polyplus-transfection Database
Search for publications in the Transfection Database with Polyplus transfection reagents or for transfection conditions. Over 6000 publications, 1000 cell lines and primary cells available.
Lexicon
This lexicon will help you to understand the different terms related to Polyplus products and services.